Two months after submitting a U.S. Biologics License Application for VEGF Trap-Eye (afilbercept ophthalmic solution) in wet age-related macular degeneration, Regeneron Pharmaceuticals Inc. and Bayer HealthCare began Phase III trials in a new indication, diabetic macular edema (DME).